Podcasts about Chronic kidney disease

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show

Enhance dialysis-dependent chronic kidney disease (DD-CKD) anemia outcomes through team-centered care and better understanding of new treatment options. Credit available for this activity expires: 12/19/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/elevating-anemia-care-new-strategies-dialysis-dependent-2025a1000zpg?ecd=bdc_podcast_libsyn_mscpedu

Chegou o episódio escolhido por vocês! Marcela Belleza e Joanne Alves convidam Carol Millon para conversar sobe 6 clinicagens de inibidores de SGLT2, as gliflozinas:Indicações além do DMRisco de CAD euglicêmicaQuando não usar?⁠Cuidados com doença aguda (sick day) e hipovolemia⁠Cuidados pré-operatórioRisco de fratura e amputaçãoReferências:1. Bailey CJ, et al. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. Published 2013 Feb 20. doi:10.1186/1741-7015-11-432. Bersoff-Matcha SJ, et al. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. Ann Intern Med. 2019;170(11):764-769. doi:10.7326/M19-00853. Chang HY, et al. Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients With Type 2 Diabetes. JAMA Intern Med. 2018;178(9):1190-1198. doi:10.1001/jamainternmed.2018.3034 4. Clar C, et al. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012 Oct 18;2(5):e001007. doi: 10.1136/bmjopen-2012-001007. PMID: 23087012; PMCID: PMC3488745.5. Das SR, et al. 2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145. doi: 10.1016/j.jacc.2020.05.037. Epub 2020 Aug 5. PMID: 32771263; PMCID: PMC7545583. 6. Fralick M, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. Published 2020 Aug 25. doi:10.1136/bmj.m28127. Li D, et al. Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017;19(3):348-355. doi:10.1111/dom.128258. Neal B, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)--a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223.e11. doi:10.1016/j.ahj.2013.05.0079. Nyirjesy P, et al. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor. Curr Med Res Opin. 2012;28(7):1173-1178. doi:10.1185/03007995.2012.69705310. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa181174411. Rosenwasser RF, et al. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. doi: 10.2147/DMSO.S34416. PMID: 24348059; PMCID: PMC3848644.12. Sridharan K, Sivaramakrishnan G. Risk of limb amputation and bone fractures with sodium glucose cotransporter-2 inhibitors: a network meta-analysis and meta-regression. Expert Opin Drug Saf. 2025;24(7):797-804. doi:10.1080/14740338.2024.237775513. Ueda P,  et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. Published 2018 Nov 14. doi:10.1136/bmj.k436514. Watts NB, et al. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18. PMID: 26580237; PMCID: PMC4701850.15. Zhuo M, et al. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Netw Open. 2021;4(10):e2130762. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.3076216. Emerson Cestari Marino, Leandra Anália Freitas Negretto, Rogério Silicani Ribeiro, Denise Momesso, Alina Coutinho Rodrigues Feitosa, Marcos Tadashi Kakitani Toyoshima, Joaquim Custódio da Silva Junior, Sérgio Vencio, Marcio Weissheimer Lauria, João Roberto de Sá, Domingos A. Malerbi, Fernando Valente, Silmara A. O. Leite, Danillo Ewerton Oliveira Amaral, Gabriel Magalhães Nunes Guimarães, Plínio da Cunha Leal, Maristela Bueno Lopes, Luiz Carlos Bastos Salles, Liana Maria Torres de Araújo Azi, Amanda Gomes Fonseca, Lorena Ibiapina M. Carvalho, Francília Faloni Coelho, Bruno Halpern, Cynthia M. Valerio, Fabio R. Trujilho,  Antonio Carlos Aguiar Brandão, Ruy Lyra e Marcello Bertoluci. Rastreamento e Controle da Hiperglicemia no Perioperatório – Posicionamento Conjunto da Sociedade Brasileira de Diabetes (SBD), Sociedade Brasileira de Anestesiologia (SBA) e Associação Brasileira para o Estudo da Obesidade e Síndrome Metabólica (ABESO). Diretriz Oficial da Sociedade Brasileira de Diabetes (2025). DOI: 10.29327/5660187.2025-10 , ISBN: 978-65-5941-367-6.17. Singh LG, Ntelis S, Siddiqui T, Seliger SL, Sorkin JD, Spanakis EK. Association of Continued Use of SGLT2 Inhibitors From the Ambulatory to Inpatient Setting With Hospital Outcomes in Patients With Diabetes: A Nationwide Cohort Study. Diabetes Care. 2024;47(6):933-940. doi:10.2337/dc23-112918. Mehta PB, Robinson A, Burkhardt D, Rushakoff RJ. Inpatient Perioperative Euglycemic Diabetic Ketoacidosis Due to Sodium-Glucose Cotransporter-2 Inhibitors - Lessons From a Case Series and Strategies to Decrease Incidence. Endocr Pract. 2022;28(9):884-888. doi:10.1016/j.eprac.2022.06.00619. Umapathysivam MM, Morgan B, Inglis JM, et al. SGLT2 Inhibitor-Associated Ketoacidosis vs Type 1 Diabetes-Associated Ketoacidosis. JAMA Netw Open. 2024;7(3):e242744. Published 2024 Mar 4. doi:10.1001/jamanetworkopen.2024.274420. Fleming N, Hamblin PS, Story D, Ekinci EI. Evolving Evidence of Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Cotransporter 2 Inhibitors. J Clin Endocrinol Metab. 2020;105(8):dgaa200. doi:10.1210/clinem/dgaa20021. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7(11):845-854. doi:10.1016/S2213-8587(19)30256-622. Braunwald E. Gliflozins in the Management of Cardiovascular Disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056/NEJMra211501123. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056/NEJMoa150472024. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa161192525. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa181238926. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa191130327. Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa202219028. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa210703829. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa202481630. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, et al. Empagliflozin in...

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-time CEO at ProKidney, a late-stage autologous cell therapy biotech focused on pioneering new treatments for chronic kidney disease (CKD), the benefits of FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, how delaying or avoiding kidney dialysis would be a game-changer for CKD patients, and more.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Chronic Kidney Disease (CKD) explained, including causes and pathophysiology, as well as symptoms and complications. We also look at diagnosis and treatment options. PDFs available here: https://rhesusmedicine.com/pages/nephrologyConsider subscribing (if you found any of the info useful!): https://www.youtube.com/channel/UCRks8wB6vgz0E7buP0L_5RQ?sub_confirmation=1Patreon: https://www.patreon.com/rhesusmedicineBuy Us A Coffee!: https://www.buymeacoffee.com/rhesusmedicineTimestamps:0:00 What is Chronic Kidney Disease?1:45 Chronic Kidney Disease Symptoms & Complications4:51 Chronic Kidney Disease Causes7:20 Chronic Kidney Disease Pathophysiology 8:14 Chronic Kidney Disease Epidemiology / Risk Factors 8:53 Chronic Kidney Disease Diagnosis10:30 Chronic Kidney Disease Treatment LINK TO SOCIAL MEDIA: https://www.instagram.com/rhesusmedicine/ReferencesNICE Clinical Knowledge Summaries (CKS). Definition of Chronic Kidney Disease. Last revised May 2025. Available at: https://cks.nice.org.uk/topics/chronic-kidney-disease/background-information/definition/ (NICE)StatPearls. Chronic Kidney Disease. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Last updated July 31 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK535404/ (NCBI, PubMed)Wikipedia contributors. Chronic kidney disease. Last updated August 2025. Available at: https://en.wikipedia.org/wiki/Chronic_kidney_disease (Wikipedia)GPCPD (HEIW Wales). Prescribing in Acute Kidney Injury (AKI). Updated 2025. Available at: https://gpcpd.heiw.wales/clinical/acute-kidney-injury-in-primary-care/prescribing-in-aki/Kidney International. Epidemiology of chronic kidney disease: an update 2022. Kidney International Supplements, 2022 Apr;12(1):7–11. Available at: https://www.kidney-international.org/article/S0085-2538(22)00518-X/fulltext (PubMed)Disclaimer: Please remember this podcast and all content from Rhesus Medicine is for educational and entertainment purposes only and is not a guide to diagnose or to treat any form of condition. The content is not to be used to guide clinical practice and is not medical advice. Please consult a healthcare professional for medical advice.

Cyrus Khambatta, Ph.D., Sean Hashmi, M.D., MS, FASN, and Robby Barbaro, MPH, provide evidence-based diet and lifestyle strategies proven to prevent diabetes and chronic kidney disease. Learn actionable steps to transform your health through nutrition. #DiabetesPrevention #KidneyHealth #DietaryStrategies

Dr. Mitch Shulman can be heard every weekday morning at 7:50 on The Andrew Carter Morning Show.

A special filmed edition of Diary of a Kidney Warrior Podcast is coming on Monday 1st December!   In this listener-led conversation, menopause specialist Dr Vikram returns to answer the questions sent in by the Kidney Warrior community about menopause and chronic kidney disease (CKD).   This new edition continues the important discussion from Episode 142: Breaking the Silence: Menopause and CKD.

Are you actively and appropriately screening for chronic kidney disease (CKD) in your patients with cardio-kidney-metabolic (CKM) conditions? Credit available for this activity expires: 11/26/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/screening-action-addressing-chronic-kidney-disease-reduce-2025a1000wsi?ecd=bdc_podcast_libsyn_mscpedu

With November being disability awareness month in South Africa and 14 November being the annual day dedicated to recognising those living with diabetes, it seemed an appropriate time to publish this interview. In this special two-part episode, I unpack my journey with chronic kidney disease in conversation with Jeremy Opperman. In episode 138, we discuss my diagnosis with Type 1 diabetes when I was six years old and trace the impact of diabetes on my life, resulting in my blindness at the age of 21. We then turn to my subsequent discovery that I was experiencing chronic kidney disease and track the steps that led to my starting on dialysis in January 2025. In episode 139 we explore how I've adapted to dialysis as a blind woman, trying to offer insights into some of the medical realities. Finally, we discuss what the future holds as I start to discover more about a possible kidney transplant. *Note: this conversation was recorded a few months ago and much has changed since then. I now have a kidney donor and am working my way through the process of preparing for the transplant. Correction: , at one point I refer to the AV graft as an artificial vascular graft. The correct term is arteriovenous Graft, which connects an artery with a vein allowing access for the dialysis to take place. Image Description: A stylised graphic of a woman with a ponytail walking with a white cane, next to an icon of an eye with curved lines suggesting vision or awareness. Below the graphic is the text:A Different Way of Seeing with Lois Strachan I'd love to hear from you – contact me at Web: https://www.loisstrachan.com/ LinkedIn: www.linkedin.com/in/lstrachan Facebook: https://www.facebook.com/loisstrachanspeaker This episode edited by Craig Strachan using Hindenburg PRO – find out more on Hindenburg.com Credits and music by Charlie Dyasi.

Doctors Lisa and Sara talk to Consultant Nephrologist Dr Darren Green about patients with Type 2 Diabetes who also have Chronic Kidney Disease and Heart Failure.  We go through a hypothetical case to illustrate some of the finer points of management that can commonly get missed or might not be appreciated. A really detailed talk full of useful practice enhancing tips for this complex group of patients.  Disclaimer: This episode was supported by Greater Manchester NHS who received support from Boehringer.  You can use these podcasts as part of your CPD - we don't do certificates but they still count :) Resources: Dr Kevin Fernando counselling diabetic patients starting an SGLT2 Inhibitors like Dapagliflozin or Empagliflozin: https://www.youtube.com/watch?v=pc99SdtlsyU Diabetes UK counselling sheets on SGLT2 inhibitors: https://www.diabetes.org.uk/about-diabetes/looking-after-diabetes/treatments/tablets-and-medication/sglt2-inhibitors Kidney Care UK Patient Booklets: https://kidneycareuk.org/get-support/free-resources/patient-information-booklets/ Pumping Marvellous Heart Failure Charity with patient resources: https://pumpingmarvellous.org/ International Society for Nephrology Toolkit for Initiating or Changing RAASi - Renin Angiotensin Aldosterone System Inhibitors (like ACEis such as Lisinopril or Ramipril, or ARBs like Candesartan on Losartan): https://www.theisn.org/initiatives/toolkits/raasi-toolkit/ Royal College of General Practitioners Acute Renal Failure Toolkit: https://elearning.rcgp.org.uk/course/info.php?id=899 CONFIDENCE trial: Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes | New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 ATLAS trial: Efficacy and safety of high-dose lisinopril in chronic heart failure patients at high cardiovascular risk, including those with diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/11071803/ Metformin lactic acidosis Metformin in Patients With Type 2 Diabetes and Kidney Disease: A Systematic Review: https://jamanetwork.com/journals/jama/article-abstract/2084896 UK AKI Summit report UKKA AKI Summit Report + Recommendations: https://share.google/7uw1GPQ5sV2riJtiV RCGP AKI follow up  post discharge recommendations: https://bjgpopen.org/content/early/2020/06/15/bjgpopen20X101054/tab-figures-data?versioned=true ___ We really want to make these episodes relevant and helpful: if you have any questions or want any particular areas covered then contact us on Twitter @PCKBpodcast, or leave a comment on our quick anonymous survey here: https://pckb.org/feedback Email us at: primarycarepodcasts@gmail.com ___ This podcast has been made with the support of GP Excellence and Greater Manchester Integrated Care Board. Given that it is recorded with Greater Manchester clinicians, the information discussed may not be applicable elsewhere and it is important to consult local guidelines before making any treatment decisions.  The information presented is the personal opinion of the healthcare professional interviewed and might not be representative to all clinicians. It is based on their interpretation of current best practice and guidelines when the episode was recorded. Guidelines can change; To the best of our knowledge the information in this episode is up to date as of it's release but it is the listeners responsibility to review the information and make sure it is still up to date when they listen. Dr Lisa Adams, Dr Sara MacDermott and their interviewees are not liable for any advice, investigations, course of treatment, diagnosis or any other information, services or products listeners might pursue as a result of listening to this podcast - it is the clinicians responsibility to appraise the information given and review local and national guidelines before making treatment decisions. Reliance on information provided in this podcast is solely at the listeners risk. The podcast is designed to be used by trained healthcare professionals for education only. We do not recommend these for patients or the general public and they are not to be used as a method of diagnosis, opinion, treatment or medical advice for the general public. Do not delay seeking medical advice based on the information contained in this podcast. If you have questions regarding your health or feel you may have a medical condition then promptly seek the opinion of a trained healthcare professional.

With November being disability awareness month in South Africa and 14 November being the annual day dedicated to recognising those living with diabetes, it seemed an appropriate time to publish this interview. In this special two-part episode, I unpack my journey with chronic kidney disease in conversation with Jeremy Opperman. In episode 138, we discuss my diagnosis with Type 1 diabetes when I was six years old and trace the impact of diabetes on my life, resulting in my blindness at the age of 21. We then turn to my subsequent discovery that I was experiencing chronic kidney disease and track the steps that led to my starting on dialysis in January 2025. In episode 139 we explore how I've adapted to dialysis as a blind woman, trying to offer insights into some of the medical realities. Finally, we discuss what the future holds as I start to discover more about a possible kidney transplant. *Note: this conversation was recorded a few months ago and much has changed since then. I now have a kidney donor and am working my way through the process of preparing for the transplant. Correction: , at one point I refer to the AV graft as an artificial vascular graft. The correct term is arteriovenous Graft, which connects an artery with a vein allowing access for the dialysis to take place. Image Description: A stylised graphic of a woman with a ponytail walking with a white cane, next to an icon of an eye with curved lines suggesting vision or awareness. Below the graphic is the text:A Different Way of Seeing with Lois Strachan I'd love to hear from you – contact me at Web: https://www.loisstrachan.com/ LinkedIn: www.linkedin.com/in/lstrachan Facebook: https://www.facebook.com/loisstrachanspeaker This episode edited by Craig Strachan using Hindenburg PRO – find out more on Hindenburg.com Credits and music by Charlie Dyasi.

Bone mineral disorder is one of the most challenging complications of chronic kidney disease, impacting bone strength, mineral balance, and even cardiovascular health. Nutrition plays a critical role in managing this condition — but the complexity of treatment often requires a skilled, multidisciplinary approach.In this episode, host Christina Rollins talks with Sarah Gilbert, MS, RD, LD, a renal nutrition expert and Clinical Assistant Professor at the University of New England, about the dietitian's role in managing bone mineral disorder in CKD.They explore:

Bridge the gap between innovation and practice: are you unlocking the potential of novel agents in dialysis-dependent chronic kidney disease (CKD) anemia? Credit available for this activity expires: 10/31/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1003063?ecd=bdc_podcast_libsyn_mscpedu

In this episode, Dr. David Traster sits down with Dr. Michael Lebowitz, DC and Dr. Noah Lebowitz, DC of Supreme Nutrition Products to uncover what's really driving the chronic disease epidemic — and how herbal medicine + integrative strategies can help turn the tide.

The FiltrateJoel Topf @kidneyboy.bsky.social‬Swapnil Hiremath @hswapnil.medsky.socialNayan Arora captainchloride.bsky.socialSopia Ambruso @sophia-kidney.bsky.socialSpecial Guests Brendon Neuen @brendonneuen.bsky.social Associate Professor and Program Lead, Renal and Metabolic at The George Institute for Global Health. Nephrologist and Director of Kidney Trials at Royal North Shore Hospital.Neuen has had three prior appearances on Freely Filtered: EMPA Kidney, DUPLEX and Sparsentan in FSGS, FLOW and SemaglutideMuthiah Vaduganathan @mvaduganathan on X. Cardiologist at Brigham and Women's Hospital and Harvard Medical School. Assistant Professor of Medicine.Editing byJoel TopfThe Kidney Connection written and performed by Tim YauShow NotesDONATE to NephJC! Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes NEJM | NephJC SummaryFIDELIO Bakris et al, NEJM 2020 | NephJC Summary; subgroup throws doubt on efficacy of finerenone in patients on flozinsFIGARO Pitt et al, NEJM 2021; subgroups clearly shows finerenone works, flozins or notNEJM editorial (wrongly) saying do not use Flozins unless on RASi Don't use dual RAS blockade ONTARGET Yusuf et al, NEJM 2008; VA NEPHRON-D Fried et al NEJM 2013Why we cannot study finerenone in HFrEF (RALES Pitt et al NEJM 1999) Muthu is jealous of GFR slope and albuminuria surrogate endpoints and wants to borrow them for HFpEF (Inker et al EHJ 2025)Combination therapy and CV outcomes in hypertension (Wang et al JAMA Card 2024 on low dose combinations and BP; Egan et al Blood Pressure 2022 review of topic) CONFIRMATION HF trial registry entry (Finerenone and Empagliflozin in hospitalized patients with HF)23:20: Nayan and Swap miss a chance to say ‘de-flozination' to discuss stopping a flozin which would allow a patient to be included in the trial Finerenone is a CYP3A4 substrate (Heinig et al Clin Pharmacokinetics 2023); Useful list of CYP3A4 inducers and inhibitors Everyone should get an ABPM (Bugeja et al CMAJ 2022)EASiKIDNEY study design Albuminuria mediates CKD benefits with Finerenone (Agarwal et al Ann Intern Med 2023)GFR slope and Albuminuria and the FDA (Taylor et al eClin Med 2025) Dapagliflozin and Eplerenone combination crossover trial (Provenzano et al JASN 2022)Joel gets promoted! (PBFluids reflection) Bluesky NephJC Chat discussion on ‘renal remission' Withdrawal of Finerenone and worse outcomes from FINEARTS (Vaduganathan et al JACC 2025)Combination therapies Analysis from Brendan and Muthu (Neuen et al Circulation 2024)Do not use KFRE when GFR > 60 (KDIGO Practice Point 2.2.4: Note that risk prediction equations developed for use in people with CKD G3–G5, may not be valid for use in those with CKD G1–G2) Finerenone vs Spironolactone trial in Primary Aldosteronism (Hu et al Circulation 2025)FIND CKD trial design (Heerspink et al NDT 2025) FINE-ONE trial design (Heerspink et al Diab Res Practice 2023) Tubular SecretionsNayan keeping his chin up as Yankees lose and Mariners follow (MLB Playoffs)Sophia's adventures with Beekeeping (Royal Jelly?) Brendon loves listening to ‘Susan' by Raye Muthu is back into Taekwondo Swap is still reading Martha Wells (Witch King on GoodReads)Joel will be hiking the Laugavegur trail in Iceland

  Doctor Adam Weaver, MD About Dr. Weaver Dr. Weaver graduated from PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE in 2019 and completed a residency at Rowan University School of Osteopathic Medicine. Dr. Adam Weaver, DO is a Hospitalist in Blackwood, NJ and has 6 years experience. Dr. Weaver currently practices at Practice and are affiliated with Jefferson Stratford Hospital. Dr. Weaver has experience treating conditions like Bacterial Sepsis, Hypokalemia and Hypertensive Heart and Chronic Kidney Disease among other conditions at varying frequencies. At present, Dr. Weaver received an average rating of 3.7/5 from patients and has been reviewed 3 times. Dr. Weaver's office is not accepting new patients. Dr. Weaver accepts multiple insurance plans. Rebecca Reigns (Mrs. Weaver) REBECCA REIGNS - PHOTO/FASHION MODEL & CO STARRING IN THE NEW FEATURE "THE PONY MOVIE" Rebecca Reigns Can Be Seen in The Soon to be Released Film "PONY"  OFFICIAL WEBSITE https://cinemaddictfilms.wixsite.com/ponymovieofficial THE PONY MOVIE OFFICIAL TRAILER https://www.youtube.com/watch?v=qN-d6sYsH3U

This issue will review: 1.     Once-weekly Ultra-processed Foods and Diet Quality in Association With Long-term Weight Change and Progression to Type 2 Diabetes Among Individuals With a History of Gestational Diabetes Mellitus—A Prospective Study 2.     Plant-Based Dietary Patterns Associated With Reduced Risk of All-Cause Mortality in Diabetes Subgroups 3.     Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes- NEJM   4.     Risk of Phimosis Associated With SGLT2i Versus GLP-1RA: A Danish Cohort Study 5.     GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapy website and by using this link: https://link.springer.com/article/10.1007/s12325-025-03366-6. All conflicts of interest can be found online. This podcast is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

In parts 1 and 2 we looked at studies that sought to determine the effects of semaglutide on kidney function. Today, in the final part of the series, we are going to discuss another such study called Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes by Perkovic et al., 2024. Get full access to Weight and Healthcare at weightandhealthcare.substack.com/subscribe

Darshali Vyas is a pulmonary and critical care fellow at Massachusetts General Hospital. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. D.A. Vyas, L.G. Eisenstein, and D.S. Jones. The Race-Correction Debates — Progress, Tensions, and Future Directions. N Engl J Med 2025;393:1029-1036.

Dr. Jeanine Cook-Garard learns about chronic kidney disease — a serious condition that affects more than 1 in 7 adults in the U.S., often without any early symptoms. We'll talk about what causes it, who's at risk, and how it can be detected and managed before it leads to kidney failure.  Let's learn how to protect your kidneys and take control of your health from her guest, Dr. Stephen Fishbane, Chief of Division of Medicine for Kidney Diseases and Hypertension, at Long Island Jewish Medical Center and North Shore University Hospital, part of Northwell Health. He is also a Professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.

In this podcast, expert Suneel Udani, MD, discusses the management of chronic kidney disease (CKD) and CKD-associated fluid overload, including an overview of treatment guidelines and various available therapies.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Daniel W. Coyne, MD, and Morgan B. Schoer, MD, about their editorial "Parathyroidectomy for Treatment of Hyperparathyroidism in CKD" from nephSAP Volume 24, Number 3.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Daniel W. Coyne, MD, and Morgan B. Schoer, MD, about their editorial "Parathyroidectomy for Treatment of Hyperparathyroidism in CKD" from nephSAP Volume 24, Number 3.

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2024:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) (0:00 – 4:09)Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) (4:10 – 9:28)Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) (9:29 – 14:23)Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH) (14:24 – 20:28)Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (BALANCE) (20:29 – 23:59)And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (24:00 - 25:23)Calling keen trainees!Trainees, med students, residents: The Rounds Table and Trial Files (https://trialfiles.substack.com/) are looking for keen individuals to support our efforts.Reach out to fralickmpf@gmail.com if you are interested in getting involved. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Send us a textWelcome back Rounds Table Listeners! Today we have a solo episode with Dr. Mike Fralick. This week, he discusses a recently published trial exploring the simultaneous initiation of SGLT2 inhibitors and finerenone (a nonsteroidal mineralocorticoid receptor antagonist) in persons with chronic kidney disease and type 2 diabetes. Here we go!Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes (0:00 – 9:28).Calling keen trainees! (9:29 - 10:28)Trainees, med students, residents: The Rounds Table and Trial Files are looking for keen individuals to support our efforts.Trial Files is a free monthly newsletter on practice-changing trials, delivered straight to your inbox (https://trialfiles.substack.com/).Reach out to fralickmpf@gmail.com if you are interested in getting involved. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Moderator: James P. Rathmell, M.D. Participants: Nikolay O. Kamenshchikov, M.D. and Lorenzo Berra, M.D. and Kamrouz Ghadimi, M.D. Articles Discussed: Perioperative Nitric Oxide Conditioning Reduces Acute Kidney Injury in Cardiac Surgery Patients with Chronic Kidney Disease (the DEFENDER Trial): A Randomized Controlled Trial Nitric Oxide and Kidney Injury after Cardiac Surgery: A Solution Looking for a Problem

Did you know that people who have received a kidney transplant are at a much higher risk for skin cancer? We sat down with experts to discuss how you can lower your risk. In this episode we heard from: Dr. Cerrene Giordano is a dermatologist and Mohs Micrographic surgeon at Roswell Park Comprehensive Cancer Center in Buffalo, New York. She specializes in treating skin cancers, particularly in patients who are high risk such as those who have received organ transplants, have weakened immune systems, or a genetic predisposition to skin cancer development. Her expertise includes skin cancer surgery, wound reconstruction, and the management of skin cancers such as melanoma, basal cell carcinoma, and squamous cell carcinoma, to name a few. Dr. Giordano is also involved in research aimed at improving pain management following dermatologic surgeries and exploring advanced imaging techniques to enhance surgical outcomes. Kent Bressler is a retired RN who was diagnosed with FSGS in 1984, and received a living donor transplant from his brother Kip in 1987. Kent is an active advocate for preemptive kidney transplant and has on the recommendation of NKF worked closely with the DoD and PCORI as a consumer peer reviewer. He is an NKF peer mentor and advocate who has collaborated on an editorial “Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of Chronic Kidney Disease,” published in AJKD in 2019. He will also be participating in the development of the new NKF Patient Network serving on the Data Input and Integration Committee. He has been an active hill advocate for the NKF for six years and was the proud recipient of the 2017 Richard K. Salick Advocacy Award. Kent is also an Army Veteran and retired from the Veterans administration as an RN. He is the co-founder of Kidney Solutions a not for profit program in Texas that assists patients and families in the transplant process and in finding a donor. He is currently an assistant team leader for Region 7. Kent and Cathy Bressler have been married for 56 years and their family consists of Gretchen and Todd Rossington and their son Colt and Celeste and Alex Brown and their children John Banks, Catherine and Alexis Brown. Risa Simon is a passionate author, speaker, mentor, kidney patient coach and advocate. As the founder and CEO of The Proactive Path and the TransplantFirst Academy, her mission is to help all kidney disease patients advocate for their best life possible—the life she now lives. As a preemptive kidney transplant recipient, Risa was able to circumvent the need for dialysis. This is her hope for all eligible kidney patients. Risa gives back a good portion of her time by serving on various advisory committees, such as the National Kidney Foundation's (NKF's) Kidney Action committee, the American Association of Kidney Patients (AAKP) program and convention committees and she chairs the Phoenix Chapter's Polycystic Kidney Disease (PKD) education committee.  She is also a member of the PKD Legacy Society and serves as a Peer Mentor for the National Kidney Foundation (NKF). Risa's message is all about empowering kidney patients to bring their voice to life.    Additional Resources: Dr. Cerrene Giordano Protect the Skin You're In Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Kent Bressler talks with Josie Maier, co-director of Project Donor—a nonprofit offering free support to living organ donor candidates. Kent reflects on his journey as a living donor kidney transplant recipient and his recent triumph over cancer. Josie sheds light on key challenges in organ donation, especially how BMI restrictions can prevent otherwise willing individuals from donating. Project Donor works to shift the conversation by helping potential donors overcome reversible barriers through free weight loss programs, smoking cessation resources, and therapy. Together, Kent and Josie highlight the urgent need for more living kidney donors and the importance of awareness. Listen in and discover how you can make a difference in this life-saving mission. For more information about Project Donor, visit projectdonor.org and to connect with Kidney Solutions, go to kidneysolutions.org. Host: Kent Bressler Producer: Jason Nunez Remember to keep breathing, and don't miss the next amazing episodes of Kent's Kidney Stories!  

Join us for an inspiring episode of the Diary of a Kidney Warrior Podcast as we sit down with Ravi—a fellow Kidney Warrior whose story is one of courage, connection, and unshakeable will. From his unexpected diagnosis of Chronic Kidney Disease (CKD) to life on dialysis, Ravi opens up about the challenges and triumphs that have shaped his journey.   What began as a routine post-holiday health concern quickly became a life-altering revelation. Ravi walks us through the early warning signs, the shock of diagnosis, and the complexities of seeking care amid a global pandemic. As dialysis buddies turned friends, Ravi and our host share a powerful camaraderie that highlights the strength found in community.   In this candid conversation, Ravi speaks openly about the physical, mental, and emotional toll of CKD—detailing side effects, collapsing from poor health, and the resilience needed to push through. Balancing a demanding career in IT, he reveals how he copes with the daily realities of dialysis and the hope of an eventual transplant.   Whether you're newly diagnosed or supporting someone with CKD, Ravi's insights offer encouragement, practical advice, and heartfelt wisdom. He champions the importance of early detection, mental well-being, and finding purpose amidst the struggle.  

Dr. Thomas Weims, Professor at UC Santa Barbara, shares his revolutionary findings on treating polycystic kidney disease through ketogenic interventions. After 25 years of research, his lab accidentally discovered that ketosis dramatically halts and even reverses PKD progression—something previously thought impossible. The medical establishment had long maintained that PKD, a genetic disease affecting 600,000 Americans, was untreatable through dietary means. Yet Weims' research demonstrates that beta-hydroxybutyrate (BHB), the primary ketone produced during ketosis, shows more potent effects than any pharmacological intervention his team tested. In a groundbreaking clinical trial, patients on a ketogenic diet experienced improved kidney function and reduced kidney volume in just three months—the first time such reversal has ever been documented in PKD. Weims explains the science behind this therapeutic approach, how it challenges entrenched medical dogma, and why this metabolic therapy may benefit all forms of chronic kidney disease. This conversation exposes how decades of medical education about diet and kidney health have been based on hypothetical papers rather than clinical evidence, offering hope to millions suffering from progressive kidney conditions.BIG IDEA"What we found more recently is that the progression of polycystic kidney disease is not really driven by gene mutations as previously thought—a patient inherits a bad gene, but that doesn't necessarily mean they will have rapidly progressing PKD."Gary Taubes Contact InfoWebsite: https://uncertaintyprinciples.substack.com/Website: https://garytaubes.com/Send Dr. Ovadia a Text Message. (If you want a response, include your contact information.) Dr. Ovadia can not respond here. To contact his team please email team@ifixhearts.com If you like what you hear, I wanna make it easier for you to take action on your health.Head over to i fix hearts.com/book to grab a copy of my book, Stay Off My Operating Table, and if you're ready to go deeper or talk to someone from my team, just go to i fix hearts.com/talk. Stay Off My Operating Table on X: Dr. Ovadia: @iFixHearts Jack Heald: @JackHeald5 Learn more: Stay Off My Operating Table on Amazon Take Dr. Ovadia's metabolic health quiz: iFixHearts Dr. Ovadia's website: Ovadia Heart Health Jack Heald's website: CultYourBrand.com Theme Song : Rage AgainstWritten & Performed by Logan Gritton & Colin Gailey(c) 2016 Mercury Retro RecordingsAny use of this intellectual property for text and data mining or computational analysis including as training material for artificial intelligence systems is strictly prohibited without express written consent from Dr. Philip Ovadia.

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review: 1.    Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes 2.    Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension Meta-Analysis 3.    The Diabetes Prevention Program and Its Outcomes Study: NIDDK's Journey Into the Prevention of Type 2 Diabetes and Its Public Health Impact 4.    Comparative effectiveness of alternative second‐line oral glucose‐lowering therapies for type 2 diabetes: a precision medicine approach applied to routine data 5.    Phase 3 Trial of Semaglutide in Metabolic Dysfunction– Associated Steatohepatitis   For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Send us a textWelcome back Rounds Table Listeners! Today we have the next episode in our Clinical Practice Guidelines series. Drs. Mike and John Fralick discuss the top takeaways from the 2024 KDIGO Clinical Practice Guidelines for chronic kidney disease. Here we go!1. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (0:00 - 24:24)Access the KDIGO 2024 "Top 10 Takeaways" PDFs here: https://kdigo.org/guidelines/ckd-evaluation-and-management/The Good Stuff:Nephrology Trial Files - https://nephrotrialfiles.substack.com/ (24:25 - 24:48)The Phoenician Scheme (24:49 - 25:33)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Send us a textThis recording features audio versions of Month Year Journal of Vascular and Interventional Radiology (JVIR) abstracts:Optimal Timing of Percutaneous Cholecystostomy across Different Grades of Acute Cholecystitis: A Retrospective Cohort Study ReadGallbladder Cryoablation for Calculous Cholecystitis Initially Treated with Percutaneous Drainage: A Prospective Trial in High-Risk Patients ReadComparative Prognostic Utility of Updated Model for End-Stage Liver Disease Scores for Prediction of Early Mortality after Transjugular Intrahepatic Portosystemic Shunt Creation ReadLong-Term Outcomes of Angioplasty and Stent Placement for Portomesenteric Vein Obstruction following Hepatobiliary and Pancreatic Surgery ReadThe Impact of Chronic Kidney Disease on Amputation and Death Rates in Patients with Peripheral Artery Disease in the United States ReadPercutaneous Microwave Ablation of Small (

Kent Bressler welcomes Glenna Frey, MSN, APRN-CNS. She has dedicated over 40 years to nephrology nursing, specializing in hemodialysis, peritoneal dialysis, and kidney transplantation. In 2017, she donated a kidney to a stranger at the Cleveland Clinic. The following year, she co-founded Kidney Donor Conversations (KDC), a nonprofit providing education and support for living kidney donation with her daughter, Amanda. Glenna serves as executive director of KDC and frequently presents programs on living kidney donation. She is a member of the American Nephrology Nurses Association and the National Kidney Donation Organization. She volunteers with the National Kidney Foundation and other kidney-focused groups. Her connection to kidney disease and transplantation is deeply personal. Many of her relatives, including her husband Bob, have Polycystic Kidney Disease (PKD). Bob has undergone dialysis and is now living with his second kidney transplant from a living donor. Her children, Amanda and Sawyer, also have PKD but currently maintain normal kidney function. Glenna is a published author and contributor to several works on kidney donation and nephrology nursing, including In Pursuit of a Better Life: The Ultimate Guide for Finding Living Kidney Donors, Thriving Post Kidney Transplant, and the Nephrology Nursing Journal. Additionally, she served as a reviewer for the 4th edition of Contemporary Nephrology Nursing. She is the author of the book Understanding Living Kidney Donation: The Best Treatment for Kidney Disease, now available on Amazon. Glenna also specializes in holistic therapies, holds a Black Belt in Tae Kwon Do, and is a Hula Hoop instructor. She resides in Northwest Ohio with her husband and enjoys time with her cat, chocolate lab, as well as crocheting, and native plant gardening. Glenna's pride and joy are her children, Amanda and Sawyer, and her granddaughter, Zora. For inquiries, contact: https://www.linkedin.com/in/glennafreyrnkidneydonor/ or visit https://www.facebook.com/LivingKidneyDonationBook For more information on Kidney Solutions and to join our supportive community, visit kidneysolutions.org Host: Kent Bressler Producer: Jason Nunez Remember to keep breathing, and don't miss the next amazing episodes of Kent's Kidney Stories!  

Send us a textWelcome back Rounds Table Listeners! Today we have another special episode— Trial Files turns two years old this June, and we're celebrating with an episode summarizing the Top 5 RCTs in the Trial Files catalogue to date. Dr. Mike Fralick takes us through five trials in 15 minutes. Here we go!1. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (0:00 - 3:08)2. Restrictive or Liberal Transfusion Strategy in Myocardial Infarction and Anemia (3:09 - 5:37)3. Once-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis (5:38 - 8:33)4. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (8:34 - 11:22)5. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (11:23 - 13:23)Happy 2nd Birthday, Trial Files!A free monthly newsletter on practice-changing trials, delivered straight to your inbox-- sign up at https://trialfiles.substack.com/ (13:24 - 14:19)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Dr. Reaves and Dr. Sarnak on "Benefits and risks of intensive blood pressure control in CKD patients: what does the current evidence tell us?" from nephSAP Vol 24, No 2.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Dr. Reaves and Dr. Sarnak on "Benefits and risks of intensive blood pressure control in CKD patients: what does the current evidence tell us?" from nephSAP Vol 24, No 2.

In this podcast, Dr. Wendy St. Peter and Dr. Katie Cardone discuss the AJHP theme issue on the management of chronic kidney disease with host and AJHP Editor in Chief Dr. Daniel Cobaugh. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

In this powerful and deeply personal episode of Diary of a Kidney Warrior Podcast, we meet Christy—an extraordinary kidney warrior whose story of resilience will inspire anyone facing life's toughest battles.   Christy takes us back to 2006, when a life-threatening crisis landed her in a coma, leading to kidney failure caused by septicaemia and peritonitis. What followed was nearly two decades of living with chronic kidney disease (CKD)—a journey marked by dialysis as a young adult, the heartbreak of a failed transplant, and the constant balancing act of managing additional health complications.   But Christy's story doesn't stop at survival. She shares how she transformed her adversity into advocacy, building a vibrant online community and launching her own podcast, Chronically Christy, to connect with and uplift other kidney patients.   With honesty and wisdom, Christy speaks about:

In this episode of Kidney Talk, Lori welcomes Dr. Richard Johnson - renowned nephrologist, author of Comprehensive Clinical Nephrology, and a pioneer in kidney disease research. Together, they dive into the fascinating connection between gut health and chronic kidney disease, exploring how good bacteria can support kidney function. Dr. Johnson shares insights on probiotics like Renadyl, leaky gut syndrome, and how gut imbalances might impact people who are on dialysis or have elevated creatinine levels. This enlightening conversation uncovers why gut health matters more than we ever imagined.

Dr. Centor discusses recent Kidney Disease: Improving Global Outcomes clinical recommendations for the care of patients with chronic kidney disease.

In this podcast, Dr. Valentin Fuster reviews findings from the SUMMIT trial, which examined how tirzepatide impacts patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD). The study revealed that while tirzepatide improved cardiovascular outcomes and slightly boosted kidney function, the benefits in CKD patients may stem from mechanisms beyond glomerular filtration alone.

View the Show Notes For This Episode Dr. Robin Rose discusses Kidney Care with Peptides with Dr. Ben Weitz. [If you enjoy this podcast, please give us a rating and review on Apple Podcasts, so more people will find The Rational Wellness Podcast. Also check out the video version on my WeitzChiro YouTube page.]   Podcast Highlights In this episode of the Rational Wellness Podcast, Dr. Ben Weitz hosts Dr. Robin Rose to discuss crucial insights into kidney health. They explore the kidney's functions, including filtering blood, regulating electrolytes, and converting vitamin D. The conversation delves into chronic kidney disease, highlighting that symptoms can arise even in stage two when GFR drops below 60. Dr. Rose emphasizes the importance of early detection and intervention, discussing concepts such as uremic dysbiosis, endothelial damage, leaky gut, and the impact of toxins. They also touch on natural and supplemental approaches to support kidney health, like using bio-regulator peptides, nutritional therapy, and plant-based diets. Additionally, Dr. Rose shares her personal experience with kidney cancer and the insights she gained during her journey to recovery.   00:26 Understanding Kidney Functions and Chronic Kidney Disease 02:10 In-Depth Discussion with Dr. Robin Rose 02:34 The Complexities of Kidney Health 04:28 Kidney and Gut Health Connection 04:54 Challenges in Measuring Kidney Function 08:48 Managing Kidney Health Through Diet and Lifestyle 28:43 Nutritional Supplements for Kidney Health 33:23 Butyrate and Gut Health 33:56 Cardiovascular Markers and Genomics 34:59 Kidney Health Botanicals 37:31 Peptides and Their Benefits 43:06 Bio-Regulator Peptides 51:31 Personal Kidney Health Journey 52:48 Hydration and Herbal Teas 54:40 Final Thoughts and Resources     ________________________________________________________________________________________________________ Dr. Robin Rose is a Medical Doctor and an expert at supporting kidney health using a wholistic approach and peptides.  She has recently published a book, Renology Peptides: Kidney Success with Bioregulator Peptides. Renology Peptides is a comprehensive clinical volume that presents an evidence-guided scholarly tool to deepen understanding of regenerative kidney medicine and bioregulator peptides. Her website is Renology is Kidney Success.    Dr. Ben Weitz is available for Functional Nutrition consultations specializing in Functional Gastrointestinal Disorders like IBS/SIBO and Reflux and also Cardiometabolic Risk Factors like elevated lipids, high blood sugar, and high blood pressure.  Dr. Weitz has also successfully helped many patients with managing their weight and improving their athletic performance, as well as sports chiropractic work by calling his Santa Monica office 310-395-3111.

https://www.nejm.org/doi/full/10.1056/NEJMoa2204233

This podcast will discuss an approach to pediatric chronic kidney disease. The podcast was created by Alexis Filyk, a second-year medical student at the University of Alberta, and Dr. Michelle Ruhl, a pediatric nephrologist at the Stollery Children's Hospital in Edmonton, Alberta.

Big Pharma pays billions for direct-to-consumer TV drug ads—is it time to ban them? Focused ultrasound obliterates liver tumors with minimal side effects; Nurse tricks woman into believing she's dying of cancer to cash in on her $1.5 million life insurance policy; Arizona bans insurance denial by AI automated systems; Study overturns view that very low-carb diets are bad for kidney disease patients; Strategies for reviving a lagging thyroid.

Send us a textIn this episode, we have Dr. Lisa Dubrofsky (Nephrology, University of Toronto) speaking about the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.Host: Dr. Catherine Leurer (Geriatrics Fellow)Sound editing by:  Krzystof KowalikSupport the show